Sanofi (SAN.CAC40)

Close: 85.46 (+0.71), Aug 12, 2022
Weak Negative

Low risk

Automatic technical analysis. Medium term, Aug 12, 2022

Sanofi has broken the floor of the rising trend channel in the medium long term, which indicates a weaker initial rising rate. The price has had a strong fall after the negative signal from the double top formation at the break down through the support at 96.46. The objective at 88.92 is now met, but the formation signals further development in the same direction. The stock is approaching support at 84.30 euro, which may give a positive reaction. However, a break downwards through 84.30 euro will be a negative signal. Volume tops and volume bottoms correspond badly with tops and bottoms in the price. Volume balance is also negative, which weakens the stock. RSI is below 30 after the falling prices of the past weeks. The stock has strong negative momentum and further decline is indicated. However, particularly in big stocks, low RSI may be a sign that the stock is oversold and that there is a chance for a reaction upwards. The stock is overall assessed as technically slightly negative for the medium long term.

Recommendation one to six months: Weak Negative (Score: -26)

Period  
Vol.bal. Volatility Liquidity +/- %
1 day-0.97%358.47+0.84%
5 days-81.463.08%418.05-12.36%
22 days-61.697.38%222.27-13.87%
66 days-45.3212.49%206.04-12.31%

More analyses of Sanofi

chart Sanofi (SAN) Candlesticks 22 Days
Candlesticks
chart Sanofi (SAN) Short term
Short term: Negative
chart Sanofi (SAN) Medium term
Medium term: Weak Negative
chart Sanofi (SAN) Long term
Long term: Weak Positive
 


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.

Titlex

OK
+